GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
A binary Xpovio catalyst is set for March.
BeOne terminates a MUC1-targeting project.
Welireg, Padcev, and a surprise fillip for Flare.
AZD0120’s first pivotal trial will test settings as early as the second line.
Two new pivotal Chinese first-line trials have started in lung cancer.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
